Cas:98604-38-7 N-(4-tert-Butylphenyl)succinimide manufacturer & supplier

Chemical Name:N-(4-tert-Butylphenyl)succinimide

CAS.NO:98604-38-7

Synonyms:N-(4-tert-Butylphenyl)succinimide

Molecular Formula:C₁₄H₁₇NO₂

Molecular Weight:231.29000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:37.38000

Exact Mass:231.12600

LogP:2.70250

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-(4-tert-Butylphenyl)succinimide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-(4-tert-Butylphenyl)succinimide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(4-tert-Butylphenyl)succinimide Use and application,N-(4-tert-Butylphenyl)succinimide technical grade,usp/ep/jp grade.

Related News: China has asked the European Union for help in buying urgently needed medical supplies from its member countries, the China��s official Xinhua news agency said on Saturday. N-(4-tert-Butylphenyl)succinimide manufacturer As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. N-(4-tert-Butylphenyl)succinimide supplier Health Canada said it was planning an onsite inspection this summer and that it would not accept any product or ingredients made at the plant until the inspection was complete. N-(4-tert-Butylphenyl)succinimide vendor Commonly used generic drugs: the products whose patents have expired and the generic drugs of many companies have participated in the competition, and the market demand is large. N-(4-tert-Butylphenyl)succinimide factory At present, China’s bulk drug industry is mainly focused on bulk drug substances, and there is huge room for development in terms of specialty drug substances and patented drug substances.